Anti-Mouse CD317 (Clone 927) – Purified in vivo PLATINUM™ Functional Grade
Pricing & Details
Mouse plasmacytoid dendritic cells
≥ 5.0 mg/ml
<0.5 EU/mg as determined by the LAL method
≥98% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
Other Applications Reported In Literature ?
In vivo depletion
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone 927 activity is directed against murine CD317 (BST2; PDCA-1).
Murine CD317 is expressed by IFN-producing cells in naïve mouse spleen and by a wide variety of cell lines including T cells, mast cells, B cells, fibroblast cells, and pluripotent embryonal carcinoma cells. Additionally, mice challenged by influenza or other stimuli (CpG, LPS, murine CMV, poly(I:C), and imiquimod) express CD317 in DC and other myeloid cells as well as T cells, B cells, NKT cells, and some NK cells. CD317 is also expressed on CD138+ plasma cells in naïve mice and is upregulated by viral stimulation.
Monoclonal antibody (mAb) 927 recognizes CD317 (BST2; PDCA-1)1. CD317 is a specific marker of IFN-producing cells (IPCs aka plasmacytoid dendritic cells, DC) under naïve conditions. IPCs are early responders to viral infection and direct both the innate and adaptive immune response2,3. CD317 also promotes secretion in IPCs, presumably by sorting proteins between the Golgi apparatus and plasma membrane1. CD317 is located on the cell surface as well as intracellularly in the Golgi apparatus and is associated with lipid rafts.
CD317 is primarily present on the cell surfaces of murine IPCs in naïve mice, where its expression on resting and activated IPCs is independent of IFNs1. However, when stimulated with type I IFNs and IFN-γ, cell surface expression of CD317 is induced on most cell types. When administered in vivo, treatment with mAb 927 abrogates IFN-α secretion by IPCs in response to CpG as well as depletes IPCs ~ 95%, significantly reducing plasma cells.
The 927 clone was generated to overcome barriers to the identification and study of IPCs caused by their scarcity in blood and tissues as well as their complex surface phenotype1. mAb 927 was generated by immunizing Wistar/CRL rats with bone marrow-derived IPCs with either CpG oligodeoxynucleotide 1826 or heat-killed Mycobacteria tuberculosis as adjuvant. Hybridoma lines were created by fusing popliteal lymph nodes with SP2/0 myeloma cells. Supernatants were screened for lines that recognize CD11c+B220+Ly-6c+CD11b-splenocytes. mAb 927 is rat IgG2b isotype.
Recently identified antiviral protein that blocks the release of nascent retrovirus or other particles from infected cells.
NCBI Gene Bank ID
References & Citations
1. Blasius AL, Giurisato E, Cella M, et al. J Immunol. 177(5):3260-3265. 2006.
2. Colonna M, Trinchieri G, Liu YJ. Nat Immunol. 5(12):1219-1226. 2004.
3. Liu YJ. Annu Rev Immunol. 23:275-306. 2005.
4. Yun TJ, Lee JS, Machmach K, et al. Cell Metab. 23(5):852-866. 2016.
5. Toivonen R, Kong L, Rasool O, et al. J Immunol. 196(11):4750-4759. 2016.
6. Moniz RJ, Chan AM, Gordon LK, et al. FEMS Immunol Med Microbiol. 58(3):397-404. 2010.
7. Rajagopal D, Paturel C, Morel Y, et al. Blood. 115(10):1949-1957. 2010.
8. Nash WT, Gillespie AL, Brown MG. Front Immunol. 8:251. 2017.
9. Bradley KC, Finsterbusch K, Schnepf D, et al. Cell Rep. 28(1):245-256.e4. 2019.
10. Schliemann C, Roesli C, Kamada H, et al. Blood. 115(3):736-744. 2010.